Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C
暂无分享,去创建一个
M. Imamura | N. Hiraga | K. Chayama | D. Miki | H. Aikata | Y. Kawakami | H. Hyogo | A. Hiramatsu | T. Fukuhara | Ayako Urabe | H. Ochi | E. Murakami | T. Kawaoka | H. Fujino | H. Kan | Keiichi Masaki | Tomoki Kobayashi | T. Nakahara | Yuko Nagaoki | M. Tsuge | N. Naeshiro | Daisuke Miyaki | Shoichi Takahashi | W. Ohishi | H. Abe | C. N. Hayes | A. Ono | S. Yokoyama | Hiroshima Liver Study Group | Y. Honda | Noriaki Naeshiro | Hiromi Kan
[1] H. Nomura,et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. , 2013, Journal of hepatology.
[2] Yoshiyuki Suzuki,et al. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon‐alpha‐2b and ribavirin in hepatitis C patients , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.
[3] M. Kudo,et al. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study , 2013, Journal of Gastroenterology.
[4] H. Nomura,et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. , 2013, Journal of hepatology.
[5] Barbara Rehermann,et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.
[6] K. Chayama,et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines , 2012, Journal of Gastroenterology.
[7] N. Hayashi,et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C , 2012, Journal of viral hepatitis.
[8] Yusuke Nakamura,et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. , 2011, The Journal of infectious diseases.
[9] Geoffrey Dusheiko,et al. Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.
[10] Yusuke Nakamura,et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir , 2011, Hepatology.
[11] Yusuke Nakamura,et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. , 2010, Gastroenterology.
[12] H. Nomura,et al. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. , 2010, World journal of gastroenterology.
[13] Yusuke Nakamura,et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin , 2010, Hepatology.
[14] K. Hayashi,et al. Efficacy of peginterferon‐α‐2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[15] Jacques Fellay,et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.
[16] Ming‐Lung Yu,et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. , 2010, The Journal of infectious diseases.
[17] Thomas Berg,et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.
[18] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[19] G. Everson,et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.
[20] Edward A Belongia,et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.
[21] Yoshiyuki Suzuki,et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. , 2007, Journal of hepatology.
[22] Yoshiyuki Suzuki,et al. Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C , 2006, Intervirology.
[23] S. Zeuzem,et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. , 2006, Gastroenterology.
[24] N. Hayashi,et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.
[25] Y. Shiratori,et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C , 2006, Hepatology.
[26] Yoshiyuki Suzuki,et al. Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load , 2006, Journal of medical virology.
[27] S. Zeuzem. Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? , 2004, Annals of Internal Medicine.
[28] Yusuke Nakamura,et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis , 2003, Nature Genetics.
[29] J. Hoofnagle,et al. National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 , 2002, Gastroenterology.
[30] T. Gojobori,et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[31] K. Reddy,et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). , 2002, Journal of hepatology.
[32] Yusuke Nakamura,et al. A high-throughput SNP typing system for genome-wide association studies , 2001, Journal of Human Genetics.
[33] F. Iber,et al. Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .
[34] N. Hayashi,et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. , 2012, Journal of hepatology.